22 November 2017; pdfCompany Announcement – Pro Medicus Showcases AI Advances at RSNA 2017 – Acrobat pdf 120k


  • Visage unveils advances in artificial intelligence (AI) at the RSNA 2017 Machine Learning Showcase.
  • Visage 7 – the only solution to combine both AI research and AI aided diagnostic interpretation capabilities in a single, enterprise imaging platform.
  • Algorithms developed by Visage as well as third parties will be demonstrated.

Leading health imaging company Pro Medicus Limited [ASX: PME] today announced that its wholly owned US subsidiary, Visage Imaging, Inc., will debut its artificial intelligence (AI) offerings at the Radiological Society of North America (RSNA) 2017 annual meeting (Visage Kiosk 8149M, North Hall B) as part of the inaugural RSNA Machine Learning Showcase (November 26-30, Chicago, Illinois).

Significant promise and investment are driving a wide range of AI initiatives in healthcare IT particularly in the area of health imaging. The company’s vision is to utilise its R&D capability and market leading technology to deliver cutting-edge AI offerings to optimize Enterprise Imaging worldwide.

Visage will showcase technology that makes Visage 7 the first and only system to combine both AI research and AI assisted diagnostic interpretation in the same Enterprise Imaging platform.

“Historically, imaging platforms for research and diagnostic purposes have been totally separate,” said Malte Westerhoff PhD, Co-founder and Global CTO of Visage Imaging. Dr Westerhoff continued, “Visage’s GPU-based architecture is ideal for AI and, combined with our open APIs, will enable us to unify research and diagnostic imaging in ways not available before. This will enable AI breakthroughs to advance patient care by giving radiologists faster access to new tools that help increase productivity and improve clinical accuracy.”

The company will also show algorithms working on the ultrafast and highly scalable Visage 7 platform. Both internally developed algorithms as well as third party algorithms from academic institutions and other companies will be demonstrated.

“AI is evolving rapidly and has the potential to transform health imaging in ways previously not imagined,” said Dr Sam Hupert, Pro Medicus CEO. “We are well placed to capitalise on this transformation as we look to leverage our three key assets, namely our R&D capability, our technology platform and our growing base of blue chip clients.”

The company’s first AI innovations for Visage 7 are works-in-progress and are scheduled to be released in the first half of 2018.